Therapeutic drug monitoring (TDM) plays a crucial role in personalized medicine. It helps clinicians to tailor drug dosage for optimized therapy through understanding the underlying complex pharmacokinetics and pharmacodynamics. Conventional, non-continuous TDM fails to provide real-time information, which is particularly important for the initial phase of immunosuppressant therapy, e.g., with cyclosporine (CsA) and mycophenolic acid (MPA).
Cornel’s MicroEye(R) microdialysis device is a key factor in enabling therapeutic drug monitoring of immunosuppressants drugs to prevent rejection in transplant patients.
Cornel Medical has been invited to join two EU consortia of leading clinical, industrial and academic partners developing patient monitoring technologies. EU grant applications have been submitted.
An excellent article in The Times (published Saturday, 27 June, 2020) If biotech transforms our health in the coming decade it will be through the creativity of individuals unconstrained by red tape, says Matt Ridley. I believe it is a extract from his book ‘How Innovation Works’. He comments that people overestimate the impact of […]
Cornel Medical is leading specialist teams from University College London and the Institute for Bio-Sensing Technology (IBST) at the University of the West of England to develop technology to provide real-time continuous monitoring of antibiotics in critically ill patients.